TORONTO, Oct. 31 /CNW/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. Dr. Ezrin will provide an update on the Company’s preparations for the planned Phase III trial for Neuradiab, a treatment for newly diagnosed glioblastoma multiforme (GBM), the most common form of brain cancer. The conference is being held at the New York Palace Hotel in New York City and Bradmer’s presentation is scheduled for Monday, November 5th at 9:10am ET in the Spellman Room.
